Lehrstuhl für Tissue Engineering und Regenerative Medizin
Refine
Has Fulltext
- yes (163)
Is part of the Bibliography
- yes (163)
Year of publication
Document Type
- Journal article (112)
- Doctoral Thesis (51)
Keywords
- Tissue Engineering (25)
- tissue engineering (11)
- regenerative medicine (7)
- stem cells (6)
- in vitro (5)
- 3D tissue model (4)
- In-vitro-Kultur (4)
- extracellular matrix (4)
- gene expression (4)
- inflammation (4)
Institute
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (163)
- Graduate School of Life Sciences (25)
- Theodor-Boveri-Institut für Biowissenschaften (22)
- Julius-von-Sachs-Institut für Biowissenschaften (8)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (6)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (6)
- Institut für Molekulare Infektionsbiologie (5)
- Institut für Organische Chemie (5)
- Institut für Virologie und Immunbiologie (5)
- Lehrstuhl für Orthopädie (5)
Sonstige beteiligte Institutionen
- Fraunhofer (1)
- Fraunhofer Institute Interfacial Engineering and Biotechnology (IGB) (1)
- Fraunhofer Institute for Integrierte Schaltungen (IIS) (1)
- IZKF (Interdisziplinäres Zentrum für Klinische Forschung), Universität Würzburg (1)
- Medizinische Universität Innsbruck (1)
- New York Blood Center (1)
- Queensland University of Technology (1)
The aim is to evaluate the effect of modifying poly[(L-lactide)-co-(epsilon-caprolactone)] scaffolds (PLCL) with nanodiamonds (nDP) or with nDP+physisorbed BMP-2 (nDP+BMP-2) on in vivo host tissue response and degradation. The scaffolds are implanted subcutaneously in Balb/c mice and retrieved after 1, 8, and 27 weeks. Molecular weight analysis shows that modified scaffolds degrade faster than the unmodified. Gene analysis at week 1 shows highest expression of proinflammatory markers around nDP scaffolds; although the presence of inflammatory cells and foreign body giant cells is more prominent around the PLCL. Tissue regeneration markers are highly expressed in the nDP+BMP-2 scaffolds at week 8. A fibrous capsule is detectable by week 8, thinnest around nDP scaffolds and at week 27 thickest around PLCL scaffolds. mRNA levels of ALP, COL1 alpha 2, and ANGPT1 are signifi cantly upregulating in the nDP+BMP-2 scaffolds at week 1 with ectopic bone seen at week 8. Even when almost 90% of the scaffold is degraded at week 27, nDP are observable at implantation areas without adverse effects. In conclusion, modifying PLCL scaffolds with nDP does not aggravate the host response and physisorbed BMP-2 delivery attenuates infl ammation while lowering the dose of BMP-2 to a relatively safe and economical level.
Die Stammzellforschung beschäftigt sich bereits seit Jahren mit der Frage, wie Gewebe oder sogar Organe im Labor hergestellt werden können. Als besonders vielversprechend erscheinen hierfür humane Mesenchymale Stammzellen (hMSC), da diese in vielen Fällen direkt vom Empfänger gewonnen werden können und so keine Organ- oder Gewebeabstoßung durch Abwehrreaktionen zu erwarten ist. Für die weitere Erforschung des Verhaltens von Stammzellen in vivo ist es notwendig, diese nicht-invasiv darstellen zu können. Dies ist zum Beispiel mittels Magnetischer Partikel Bildgebung (MPI) möglich. Hierfür müssen die Stammzellen mit einer geeigneten Substanz markiert werden. Eine solche sind beispielsweise superparamagnetische Eisenoxidnanopartikel (SPION). Derzeit gibt es keine von den medizinischen Zulassungsbehörden zugelassenen SPION die ohne TA in hMSC aufgenommen werden. In der hier vorliegenden Arbeit sollte also im Rahmen des
EU-weiten „IDEA-Projekts“ ein geeigneter SPION identifiziert werden, der eine optimale Zell-Partikel-Interaktion aufweist und sowohl mittels MPI als auch mit Raman-Spektroskopie nachweisbar ist. Zudem sollte die Nachweisbarkeit des SPION über einen längeren Zeitraum gegeben und kein Einfluss auf die hMSC feststellbar sein. Es wurden hMSC mit den Eisenoxidnanopartikeln M4E, M4F, M4F2 und M3A-PDL in unterschiedlichen Konzentrationen markiert. Für M3A-PDL und M4E erfolgten bei einer Konzentration von 0,5 mg/ml Untersuchungen in Zellkultur sowie auf SIS-ser als Matrix im 3D-Modell. Desweiteren wurde das Differenzierungsverhalten der mit M4E markierten hMSC bei chondrogener Differenzierung untersucht. Außerdem kamen Magnetische Partikel Spektroskopie (MPS) und Raman-Spektroskopie als nicht-invasive Nachweisverfahren zum Einsatz. Der SPION-Nachweis erfolgte histologisch mittels Berliner Blau Färbung. Untersuchungen zu Zellviabilität und Proliferation erfolgten durch Trypanblau sowie Ki67-Antikörper-Färbung. Um Nachzuweisen ob auch markierte Zellen proliferieren wurde eigens ein kombiniertes Färbeprotokoll zur Kombination von Berliner Blau und immunhistochemischer Färbung
etabliert. Der Erfolg der chrondrogenen Differenzierung wurde mittels Alcianblau, Aggrecan- und Kollagen-II-Antikörper Färbung überprüft. Es konnte gezeigt werden, dass M4E bei der Markierung von hMSC eine sehr gute Zell-Partikel-Interaktion aufweist und im Gegensatz zu M3A auch ohne TA in die Zellen aufgenommen wird. Durch beide Partikel werden Zellviabilität und Proliferation nicht beeinflusst. M4F sowie M4F2 ist zur Markierung nicht geeignet. Die Markierung ließ sich im 3D-Modell mit vier Wochen deutlich länger nachweisen als in 2D Zellkultur mit maximal zwei Wochen. Die chondrogene Differenzierung wird durch die Markierung mit 0,5 mg/ml M4E beeinflusst. M3A-PDL sind durch MPS nachweisbar. Die Raman-Spektroskopie eignet sich zur Differenzierung zwischen mit M3A-PDL markierten und unmarkierten hMSC. Es ist im Rahmen dieser Arbeit gelungen, einen
Eisenoxidnanopartikel mit hervorragender Zell-Partikel-Interaktion zu identifizieren, der ohne zusätzliches TA eine intensive Markierung der hMSC ermöglicht und mit MPS nachweisbar ist. Für M4E konnte in weiteren Arbeiten am Institut bereits gezeigt werden, dass auch eine Differenzierung zwischen markierten und unmarkierten Zellen mittels Raman-Spektroskopie möglich ist. Die chondrogene Differenzierung der hMSC wurde in der vorliegenden Arbeit allerdings beeinträchtigt. In der Literatur finden sich Hinweise auf eine dosisabhängige Inhibition der Differenzierung. Es sind daher weitere Versuche notwendig, um herauszufinden, ob die Inhibition der Differenzierung möglicherweise bei geringerer SPION-Konzentration weniger ausgeprägt ist. Zudem sollte untersucht werden, ob auch geringere Konzentrationen in den Zellen über mehrere Wochen mittels MPS nachweisbar bleiben. Desweiteren sollten Untersuchungen in, der in vivo Situation ähnlicheren,
Systemen, wie dem dynamischen Umfeld einer BioVaSc-TERM® durchgeführt werden um bessere Vorhersagen zum Verhalten markierter hMSC in vivo treffen zu können.
Feasibility Study on a Microwave-Based Sensor for Measuring Hydration Level Using Human Skin Models
(2016)
Tissue dehydration results in three major types of exsiccosis—hyper-, hypo-, or isonatraemia. All three types entail alterations of salt concentrations leading to impaired biochemical processes, and can finally cause severe morbidity. The aim of our study was to demonstrate the feasibility of a microwave-based sensor technology for the non-invasive measurement of the hydration status. Electromagnetic waves at high frequencies interact with molecules, especially water. Hence, if a sample contains free water molecules, this can be detected in a reflected microwave signal. To develop the sensor system, human three-dimensional skin equivalents were instituted as a standardized test platform mimicking reproducible exsiccosis scenarios. Therefore, skin equivalents with a specific hydration and density of matrix components were generated and microwave measurements were performed. Hydration-specific spectra allowed deriving the hydration state of the skin models. A further advantage of the skin equivalents was the characterization of the impact of distinct skin components on the measured signals to investigate mechanisms of signal generation. The results demonstrate the feasibility of a non-invasive microwave-based hydration sensor technology. The sensor bears potential to be integrated in a wearable medical device for personal health monitoring.
Induction of ectopic bone formation by site directed immobilized BMP2 variants \(in\) \(vivo\)
(2020)
In contrast to common bone fractures, critical size bone defects are unable to self-regenerate and therefore external sources for bone replacement are needed. Currently, the gold standard to treat critical size bone fractures, resulting from diseases, trauma or surgical interventions, is the use of autologous bone transplantation that is associated with several drawbacks such as postoperative pain, increased loss of blood during surgery and extended operative time.
The field of bone tissue engineering focuses on the combination of biomaterials and growth factors to circumvent these adverse events and thereby to improve critical size bone defects treatment.
To this aim, a promising approach is represented by using a collagen sponge soaked with one of the most powerful osteoinductive proteins, the bone morphogenetic protein 2 (BMP2). After the approval by the Food and Drug Administration (FDA), BMP2 was used to successfully treat several severe bone defects. However, the use of BMP2 delivery systems is associated with severe side effects such as inflammation, swelling, ectopic bone formation outside of the site of implantation and breathing problems if implanted in the area of the cervical spine. The occurrence of severe side effects is related to the supraphysiological amounts of the applied protein at the implantation site. The BMP2 is typically adsorbed into the scaffold and diffuses rapidly after implantation. Therefore, intensive research has been conducted to improve the protein’s retention ability, since a prolonged entrapment of the BMP2 at the implantation site would induce superior bone formation in vivo due to a minimized protein release. By controlling the release from newly designed materials or changing the protein immobilization methods, it seems possible to improve the osteoinductive properties of the resulting BMP2-functionalized scaffolds.
The combination of biocompatible and biodegradable scaffolds functionalized with a covalently immobilized protein such as BMP2 would constitute a new alternative in bone tissue engineering by eliminating the aforementioned severe side effects. One of the most common immobilization techniques is represented by the so-called EDC/NHS chemistry. This coupling technique allows covalent biding of the growth factor but in a non-site direct manner, thus producing an implant with uncontrollable and unpredictable osteogenic activities. Therefore, the generation of BMP2 variants harboring functional groups that allow a site-directed immobilization to the scaffold, would enable the production of implants with reproducible osteogenic activity.
The new BMP2 variants harbor an artificial amino acid at a specific position of the mature polypeptide sequence. The presence of the unnatural amino acid allows to use particular covalent immobilization techniques in a highly specific and site directed manner. The two selected BMP2 variants, BMP2 E83Plk and BMP2 E83Azide, were expressed in E. coli, renatured and purified by cation exchange chromatography. The final products were intensively analyzed in terms of purity and biological activity in vitro. The two BMP2 variants enabled the application of different coupling techniques and verify the possible options for site directed immobilization to the scaffold.
Intensive analyses on the possible side effects caused by the coupling reactions and on the quantification of the coupled protein were performed. Both click chemistry reactions showed high reaction efficacies when the BMP2 variants were coupled to functionalized fluorophores. Quantification by ELISA and scintillation counting of radioactively labeled protein revealed different outcomes. Moreover, the amounts of protein detected for the BMP2 variants coupled to microspheres were similar to that of the wild type protein. Therefore, it was not possible to conclude whether the BMP2 variants were covalently coupled or just adsorbed.
BMP2 variants being immobilized to various microspheres induced osteogenic differentiation of C2C12 cells in vitro, but only in those cells that were located in close proximity to the functionalized beads. This selectivity strongly indicates that the protein is for a great portion covalently coupled and not just adsorbed. Moreover, the difference between the covalently coupled BMP2 variants and the adsorbed BMP2 WT was confirmed in vivo. Injection of the BMP2-functionalized microspheres in a rat model induced subcutaneous bone formation.
The main aim of the animal experiment was to prove whether covalently coupled BMP2 induces bone formation at significant lower doses if compared to the amount being required if the protein is simply adsorbed. To this aim, several BMP2 concentrations were tested in this animal experiment. The BMP2 variants, being covalently immobilized, were hypothesized to be retained and therefore bio-available at the site of implantation for a prolonged time. However, in the animal experiments, lower doses of either coupled or adsorbed protein were unable to induce any bone formation within the 12 weeks.
In contrast, the highest doses induced bone formation that was first detected at week 4. During the 12 weeks of the experiment, an increase in bone density and a steady state bone volume was observed. These results were obtained only for the covalently coupled BMP2 E83Azide but not for BMP2 E83Plk that did not induce bone formation in any condition. The negative outcome after application of BMP2 E83Plk suggested that the coupling reaction might have provoked changes in the protein structure that extremely influenced its osteogenic capabilities in vivo.
However, the histological examination of the different ossicles induced either by BMP2 WT or BMP2 E83Azide, revealed clear morphological differences. BMP2 WT induced a bone shell-like structure, while the covalently coupled protein induced uniform bone formation also throughout the inner part. The differences between the two newly formed bones can be clearly associated with the different protein delivery mechanisms. Thus, the developed functionalized microspheres constitute a new interesting strategy that needs further investigations in order to be able to be used as replacement of the currently used BMP2 WT loaded medical devices.
Despite advancements of modern medicine, the number of patients with the the end-stage kidney disease keeps growing, and surgical procedures to establish and maintain a vascular access for hemodialysis are rising accordingly. Surgical access of choice remains autogenous arteriovenous fistula, whereas approach “fistula first at all costs” leads to failure in certain subgroups of patients. Modern synthetic vascular grafts fail to deliver long-term results comparable with AV fistula. With all that in mind, this work has an aim of developing a new alternative vascular graft, which can be used for hemodialysis access using the methods of TE, especially electrospinning technique. It is hypothesized that electrospun scaffold, made of PCL and collagen type I may assemble mechanical properties similar to native blood vessels. Seeding such electrospun scaffolds with human microvascular endothelial cells (hmvECs) and preconditioning with shear stress and continuous flow might achieve sufficient endothelial lining being able to resist acute thrombosis. One further topic considered on-site infections, which represents one of the most spread complications of dialysis therapy due to continuous needle punctures. The main hypothesis was that during electrospinning process, polymers can be blended with antibiotics with the aim of producing scaffolds with antimicrobial properties, which could lead to reducing the risk of on-site infection on one side, while not affecting the cell viability.
Tumor models based on cancer cell lines cultured two-dimensionally (2D) on plastic lack histological complexity and functionality compared to the native microenvironment. Xenogenic mouse tumor models display higher complexity but often do not predict human drug responses accurately due to species-specific differences. We present here a three-dimensional (3D) in vitro colon cancer model based on a biological scaffold derived from decellularized porcine jejunum (small intestine submucosa+mucosa, SISmuc). Two different cell lines were used in monoculture or in coculture with primary fibroblasts. After 14 days of culture, we demonstrated a close contact of human Caco2 colon cancer cells with the preserved basement membrane on an ultrastructural level as well as morphological characteristics of a well-differentiated epithelium. To generate a tissue-engineered tumor model, we chose human SW480 colon cancer cells, a reportedly malignant cell line. Malignant characteristics were confirmed in 2D cell culture: SW480 cells showed higher vimentin and lower E-cadherin expression than Caco2 cells. In contrast to Caco2, SW480 cells displayed cancerous characteristics such as delocalized E-cadherin and nuclear location of beta-catenin in a subset of cells. One central drawback of 2D cultures-especially in consideration of drug testing-is their artificially high proliferation. In our 3D tissue-engineered tumor model, both cell lines showed decreased numbers of proliferating cells, thus correlating more precisely with observations of primary colon cancer in all stages (UICC I-IV). Moreover, vimentin decreased in SW480 colon cancer cells, indicating a mesenchymal to epithelial transition process, attributed to metastasis formation. Only SW480 cells cocultured with fibroblasts induced the formation of tumor-like aggregates surrounded by fibroblasts, whereas in Caco2 cocultures, a separate Caco2 cell layer was formed separated from the fibroblast compartment beneath. To foster tissue generation, a bioreactor was constructed for dynamic culture approaches. This induced a close tissue-like association of cultured tumor cells with fibroblasts reflecting tumor biopsies. Therapy with 5-fluorouracil (5-FU) was effective only in 3D coculture. In conclusion, our 3D tumor model reflects human tissue-related tumor characteristics, including lower tumor cell proliferation. It is now available for drug testing in metastatic context-especially for substances targeting tumor-stroma interactions.
Over the last 20 years, there has been increasing focus on the development of novel stem cell based therapies for the treatment of disorders and diseases affecting the enteric nervous system (ENS) of the gastrointestinal tract (so-called enteric neuropathies). Here, the idea is that ENS progenitor/stem cells could be transplanted into the gut wall to replace the damaged or absent neurons and glia of the ENS. This White Paper sets out experts' views on the commonly used methods and approaches to identify, isolate, purify, expand and optimize ENS stem cells, transplant them into the bowel, and assess transplant success, including restoration of gut function. We also highlight obstacles that must be overcome in order to progress from successful preclinical studies in animal models to ENS stem cell therapies in the clinic.
To replace the Draize skin irritation assay (OECD guideline 404) several test methods based on reconstructed human epidermis (RHE) have been developed and were adopted in the OECD test guideline 439. However, all validated test methods in the guideline are linked to RHE provided by only three companies. Thus,the availability of these test models is dependent on the commercial interest of the producer. To overcome this limitation and thus to increase the accessibility of in vitro skin irritation testing, an open source reconstructed epidermis (OS-REp) was introduced. To demonstrate the capacity of the OS-REp in regulatory risk assessment, a catch-up-validation study was performed. The participating laboratories used in-house generated OS-REp to assess the set of 20 reference substances according to the performance standards amending the OECD test guideline 439. Testing was performed under blinded conditions. The within-laboratory reproducibility of 87% and the inter-laboratory reproducibility of 85% prove a high reliability of irritancy testing using the OS-REp protocol. In addition, the prediction capacity was with an accuracy of 80% comparable to previous published RHE based test protocols. Taken together the results indicate that the OS-REp test method can be used as a standalone alternative skin irritation test replacing the OECD test guideline 404.
This study aimed to evaluate the tumorigenic potential of functionalising poly(LLA-co-CL) scaffolds. The copolymer scaffolds were functionalised with nanodiamonds (nDP) or with nDP and physisorbed BMP-2 (nDP-PHY) to enhance osteoinductivity. Culturing early neoplastic dysplastic keratinocytes (DOK\(^{Luc}\)) on nDP modified scaffolds reduced significantly their subsequent sphere formation ability and decreased significantly the cells' proliferation in the supra-basal layers of in vitro 3D oral neoplastic mucosa (3D-OT) when compared to DOK\(^{Luc}\) previously cultured on nDP-PHY scaffolds. Using an in vivo non-invasive environmentally-induced oral carcinogenesis model, nDP scaffolds were observed to reduce bioluminescence intensity of tumours formed by DOK\(^{Luc}\) + carcinoma associated fibroblasts (CAF). nDP modification was also found to promote differentiation of DOK\(^{Luc}\) both in vitro in 3D-OT and in vivo in xenografts formed by DOKLuc alone. The nDP-PHY scaffold had the highest number of invasive tumours formed by DOK\(^{Luc}\) + CAF outside the scaffold area compared to the nDP and control scaffolds. In conclusion, in vitro and in vivo results presented here demonstrate that nDP modified copolymer scaffolds are able to decrease the tumorigenic potential of DOK\(^{Luc}\), while confirming concerns for the therapeutic use of BMP-2 for reconstruction of bone defects in oral cancer patients due to its tumour promoting capabilities.
Als die häufigste tödliche Tumorerkrankung weltweit ist das Lungenkarzinom mit einer sehr schlechten Prognose verbunden. Eine Behandlungsoption für Lungenadenokarzinome, die eine aktivierende EGFR-Mutation aufweisen, ist der orale EGFR-TKI Gefitinib (Iressa®, ZD1839). Die Resistenzentwicklung von Tumoren gegen diese Therapie stellt ein großes klinisches Problem dar.
Das Ziel dieser Arbeit war es, die Dosis-Wirkungs-Beziehung von Gefitinib, sowie die Entwicklung von Resistenzen in einem etablierten humanen 3D Lungentumormodell zu untersuchen und dieses Testsystem für eben diese Fragestellungen zu validieren.
Vorliegende Arbeit bestätigt, dass pharmakologische Untersuchungen in Zellkulturen häufig zu einer Überschätzung des Behandlungserfolges führen. Das verwendete Modell entspricht mehr den in vivo Bedingungen. In dieser Arbeit wurden zwei ATP-Zellvitalitätsassays für die statischen 3D Lungentumormodelle etabliert und erfolgreich angewendet. Dabei zeigte sich eine konzentrationsabhängige Wirkung von Gefitinib auf das Wachstum, die Proliferation, die Apoptose, die Markerexpression sowie die Signalwegsaktivierungen. Im statischen 3D Lungentumormodell lag der IC50-Wert zwischen 0,05-0,1 µM Gefitinib welches den Werten aus klinischen Beobachtungen entspricht. Auch der in der Klinik bereits nach wenigen Stunden eintretende zeitliche Effekt von Gefitinib konnte in unserem Modell bestätigt werden. Eine dynamische Kultivierung der Lungentumorzellen, mit von Scherkräften verursachtem schnellerem Zellwachstum, führte zu einer weiteren Annährung an die klinischen Gegebenheiten. Das Netzwerk der Gefitinib-Wirkung auf die EGFR-Signalkaskade wurde in unserem Modell charakterisiert.
Die Betrachtung einer resistenten Zell-Subpopulation zeigte einen Resistenzmechanismus über eine Epitheliale-Mesenchymale-Transition. Zusätzlich wurde versucht, eine neue medikamenten-resistente Zell-Subpopulation zu generieren.
Das beschriebene 3D Lungentumormodell ermöglicht richtungsweisende Untersuchungen zu Dosis-Wirkungs-Beziehung von Gefitinib. Ansätze für eine weitere Optimierung des Modells wurden herausgearbeitet.